pentobarbital decreases effects of sufentanil SL by impacting hepatic/intestinal enzyme CYP3A4 metabolism. Modify Therapy/Watch Carefully. Coadministration of CYP3A4 inducers could decrease sufentanil amounts and efficacy, probably precipitating withdrawal syndrome in people who may have developed Bodily dependence to sufentanil. Discontinuation of concomitantly used CYP3A4 inducers may well maximize sufentanil plasma concentration.

pentobarbital will reduce the extent or effect of mavacamten by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Contraindicated.

pentobarbital will lessen the extent or effect of darifenacin by influencing hepatic/intestinal enzyme CYP3A4 metabolism. Use Warning/Monitor.

pentobarbital will decrease the level or effect of prednisone by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Warning/Monitor.

DOSAGE AND ADMINISTRATION Dosages of barbiturates has to be individualized with full knowledge of their unique traits and encouraged rate of administration.

pentobarbital will lower the extent or effect of armodafinil by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Minor/Significance Unidentified.

pentobarbital will reduce the extent or effect of alosetron by influencing hepatic/intestinal enzyme CYP3A4 metabolism. Minimal/Importance Unfamiliar.

pentobarbital will reduce the level or effect of pioglitazone by influencing hepatic/intestinal enzyme CYP3A4 metabolism. Minimal/Significance Unidentified.

pentobarbital will lessen the extent or effect of artemether/lumefantrine by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Prevent or Use Alternate Drug. Coadministration with robust CYP3A4 inducers may result in reduced serum concentrations and loss of antimalarial efficacy

pentobarbital will minimize the extent or effect of efavirenz by impacting hepatic/intestinal enzyme CYP3A4 metabolism. Minimal/Importance Mysterious.

pentobarbital will reduce the level or effect of rolapitant by impacting hepatic/intestinal enzyme CYP3A4 metabolism. Stay clear of or Use Alternate Drug. Prolonged-time period coadministration of potent CYP3A4 inducers with rolapitant may well significantly decrease rolapitant efficacy.

pentobarbital will lessen the extent or effect of colchicine by impacting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Keep track of.

pentobarbital will decrease the extent or effect of tofacitinib by impacting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Observe. Lack of, or diminished response to tofacitinib could come about when coadministered with potent CYP3A4 inducers

Despite the fact that not suggested being a routine treatment, hemodialysis may be used in significant barbiturate intoxications or Should the affected person is anuric or in shock. Client should be rolled from side to read more side each and every half an hour. Antibiotics need to be given if pneumonia is suspected. Suitable nursing care to stop hypostatic pneumonia, decubiti, aspiration, and other issues of clients with altered states of consciousness.